Brokerages predict that Bruker Co. (NASDAQ:BRKR) will post earnings of $0.59 per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Bruker’s earnings. The highest EPS estimate is $0.60 and the lowest is $0.57. Bruker posted earnings of $0.54 per share in the same quarter last year, which suggests a positive year over year growth rate of 9.3%. The business is scheduled to report its next quarterly earnings results on Monday, February 10th.

On average, analysts expect that Bruker will report full year earnings of $1.63 per share for the current fiscal year, with EPS estimates ranging from $1.61 to $1.64. For the next financial year, analysts expect that the firm will post earnings of $1.83 per share, with EPS estimates ranging from $1.78 to $1.88. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Bruker.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, October 31st. The medical research company reported $0.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.05. Bruker had a return on equity of 28.02% and a net margin of 10.20%. The business had revenue of $521.10 million during the quarter, compared to analyst estimates of $493.52 million. During the same quarter in the previous year, the firm posted $0.37 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year.

BRKR has been the subject of a number of analyst reports. Stifel Nicolaus initiated coverage on Bruker in a research report on Thursday, November 14th. They set a “hold” rating and a $53.00 price objective for the company. BidaskClub lowered Bruker from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Citigroup began coverage on Bruker in a research report on Monday, January 6th. They set a “buy” rating and a $52.00 price target for the company. Bank of America upgraded Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price target for the company in a research report on Thursday, September 26th. Finally, ValuEngine upgraded Bruker from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $50.23.

In other Bruker news, Director Marc A. Kastner sold 3,203 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $47.39, for a total transaction of $151,790.17. Following the completion of the transaction, the director now owns 7,608 shares in the company, valued at approximately $360,543.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 26.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Huntington National Bank bought a new stake in shares of Bruker in the 4th quarter worth $32,000. Global Retirement Partners LLC raised its stake in shares of Bruker by 202.6% in the 3rd quarter. Global Retirement Partners LLC now owns 1,413 shares of the medical research company’s stock worth $62,000 after buying an additional 946 shares in the last quarter. NumerixS Investment Technologies Inc raised its stake in shares of Bruker by 153.2% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,532 shares of the medical research company’s stock worth $126,000 after buying an additional 1,532 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Bruker in the 3rd quarter worth $179,000. Finally, First Allied Advisory Services Inc. bought a new stake in shares of Bruker in the 2nd quarter worth $212,000. Institutional investors own 68.92% of the company’s stock.

NASDAQ:BRKR traded down $0.37 during midday trading on Friday, reaching $53.63. 692,474 shares of the company traded hands, compared to its average volume of 404,612. Bruker has a twelve month low of $33.78 and a twelve month high of $54.49. The firm has a market capitalization of $8.31 billion, a price-to-earnings ratio of 40.63, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.23 and a quick ratio of 1.32. The company has a fifty day moving average price of $50.87 and a 200 day moving average price of $46.83.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 2nd were given a dividend of $0.04 per share. The ex-dividend date of this dividend was Friday, November 29th. This represents a $0.16 dividend on an annualized basis and a yield of 0.30%. Bruker’s dividend payout ratio (DPR) is presently 11.43%.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: Put Option

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.